PearceIP Blog

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Samsung Bioepis obtains MA for biosimilar ranibizumab (Amelivu®) in Korea

By Bioblast Editor | May 16, 2022

Read more

Korea Biomedical Review reported that Samsung Bioepis has received marketing approval for Amelivu® (biosimilar ranibizumab) in Korea. Amelivu® will be launched in Korea after June 2022 in accordance with Samsung Bioepis’ licence from Lucentis® developer Genentech. The Kor...
Alvotech announces study results for AVT04, biosimilar ustekinumab

By Bioblast Editor | May 16, 2022

Read more

Alvotech announced positive top-line results from a 3 arm, parallel design study conducted in Australia and New Zealand regarding AVT04 (ustekinumab biosimilar), reporting that the study results demonstrate bioequivalence between AVT04 and Janssen’s Stelara®. Teva and Stad...
Too late to challenge amendments once infringement proceedings commenced

By Naomi Pearce | May 12, 2022

Read more

Illinois Tool Works Inc v Airco Fasteners Pty Ltd [2022] FCA 495

Date:

Court:

Judge:

5 May 2022

Federal Court of Australia
Medicinal Cannabis in Australia | Part 4: Protecting plant-related innovation in Australia

By Pearce IP | May 12, 2022

Read more

Innovation developed from plants and plant-derived material can be substantial and includes biotech crops, food production, feed, fibres, fuel and pharmaceuticals. However, as deta...
When supply of a staple commercial product is not infringement

By Naomi Pearce | May 11, 2022

Read more

Hood v Down Under Enterprises International Pty Ltd [2022] FCAFC 69

Date:

Court:

Judges:

4 May 2022

Full Federal Court of Aust...
Medicinal Cannabis in Australia | Part 3: Beyond PBR - IP rights and medicinal cannabis

By Pearce IP | May 11, 2022

Read more

As medicinal cannabis (MC) becomes more established in the medicinal sector due to regulatory and attitudinal changes, there has been a corresponding worldwide increase in applicati...
Alvotech to hold an Extraordinary General Meeting

By Bioblast Editor | May 11, 2022

Read more

Alvotech announced that it will hold an Extraordinary General Meeting of shareholders to approve the pending business combination with Oaktree Acquisition Corp. II. (Oaktree) on 07 June 2022. Alvotech has filed the proxy statement/prospectus with the US SEC and the SEC has...
Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways

By Naomi Pearce | May 10, 2022

Read more

Introduction
As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not registered on the Australian Register of Therapeutic Goods (ARTG)....
JSR Life Sciences announces the launch of Similis Bio

By Bioblast Editor | May 10, 2022

Read more

JSR Life Sciences announced the launch of a new business division, Similis Bio. Similis Bio plans to operate a partnering program to help biopharmaceutical companies improve the efficiency and cost of biosimilar development programs.
Merck to present data on six medicines at ASCO 2022

By Bioblast Editor | May 10, 2022

Read more

Merck announced that it will present data from studies of six medicines and pipeline candidates in more than 25 cancers at the 2022 American Society of Clinical Oncology Annual Meeting in June. This will include data on Keytruda® (ustekinumab), Lenvima® (lenvatinib) and it...